Detection of cancer stem cells in ovarian cancer

Česká verzia

Authors: A. Bartáková ¹; K. Pecková ²; O. Daum ²; J. Bouda ¹
Authors place of work: Gynekologicko-porodnická klinika LF UK a FN, Plzeň, přednosta doc. MUDr. Z. Novotný, CSc. ¹; Šiklův patologicko-anatomický ústav LF UK a FN, Plzeň, přednosta prof. MUDr. M. Michal ²
Published in the journal: Ceska Gynekol 2014; 79(1): 7-11

Summary

Objective:
Detection of cancer stem cells (CSCs) in ovarian cancer, influence of CSCs on overall survival, disease free interval. Results in comparison with literature.

Design:
Original study.

Settings:
Department of Gynaecology and Obstetrics, Faculty Hospital Pilsen and Medical Faculty in Pilsen, Charles University, Šikl’s Institute of Pathology, Faculty Hospital Pilsen and Medical Faculty in Pilsen, Charles University.

Methods:
23 specimens of papillary-serous ovarian carcinoma and 4 specimens of endometroid ovarian carcinoma were included in the study. Specific antibodies to CD44 and CD133 antigens were used. Immunoreaction of both CD44 and CD133 was evaluated for the high power field.

Results:
There was no significant correlation between CD44 expression and disease free interval and overall survival. CD133 expression was not evaluated due to an inadequate immunoreaction antibody – antigene.

Conclusion:
We did not find any statistically correlation between CD44 expression and overall survival and disease free interval in our series of patients with ovarian carcinoma. It seems to be better to use different antibody for CD133 detection.

Keywords:
CD44 – CD133 – cancer stem cells – ovarian cancer

Zdroje

1. Aruffo, A., Stamenkovic, I., Melnick, M., et al. CD44 is the principal cell surface receptor for hyaluronate. Cell, 1990, 61, p. 1303–1313.

2. Ferrandina, G., et. al. CD133 antigen expression in ovarian cancer. BMC Cancer, 2009, 9, p. 221, http://www.biomedcentral.com/1471-2407/9/221.

3. Luo, L., Zeng, J., Liang, B., et al. Ovarian cancer cells with the CD117 phenotype are highly tumorigenic and are related to chemotherapy outcome. Exp Mol Pathol, 2011, 91, 2, p. 596–602.

4. Národní onkologický registr,

www.svod.cz/report.php?diag=C56

5. Ricci, F., et al. ALDH enzymatic aktivity and CD133 positivity and response to chemoterapy in ovarian cancer patients. Am J Cancer Res, 2013, 3, 2, p. 221–229.

6. Sillanpää, S., et al. CD44 expression indicates favorable prognosis in epithelial ovarian cancer. Clin Cancer Res, 2003, 9, p. 5318–5324.

7. Stamenkovic, I., Amiot, M., Pesando, JM., Seed, B. A lymphocyte molecule implicated in lymph node homing is a member of the cartilage link protein family. Cell, 1989, 56, p. 1057–1062.

8. Steffensen, KD., Alvero, AB., Yang, Y., et al. Prevalence of epithelial ovarian cancer stem cells correlates with recurrence in early-stage ovarian cancer. 2011, 620523, http://dx.doi.org/10.1155/2011/620523.

9. Zhang, J., et al. CD133 expression associated with poor prognosis in ovarian cancer. Mod Pathol, 2012, 25, 455–456.

10. Zhang, J., Chang, B., Jinsong, L. CD44 standard form expression is correlated with high-grade ovarian carcinoma but not prognosis. Hum Pathol, 2013, 44, 9, p. 1882–1889.

11. Wang, YC., et al. ALDH1-bright epithelial ovarian cancer cells are associated with CD44 expression, drug resistance, and poor clinical outcome. Am J Pathol, 2012, 180, 3, p. 1159–1569.